Navigation Links
Double Eagle Holdings Enters Into Supply Agreement with Platform Delivery Technologies Inc.
Date:7/14/2011

AVENTURA, Fla., July 14, 2011 /PRNewswire/ -- Double Eagle Holdings, Ltd. (OTCQB: DEGH), the parent company of Fuse Science, Inc. (www.fusescience.com), announced today that it has entered into a research and development agreement with Platform Delivery Technologies Inc. (PDT Inc.), a California-based pharmaceutical consulting firm. Double Eagle Holdings is the parent company of Fuse Science, Inc., the developer of new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.

The team at PDT Inc. has been responsible for numerous product formulations currently on the market, including line extensions for Chloraseptic, private label electrolyte replacement formulas for national drugstore chains, Zicam Cold formulas and several prescription pharmaceuticals. The PDT Inc. team has more than 30 pending and issued patents in the pharmaceutical and sports performance industries.

"PDT Inc. has provided exclusive formulations and proprietary branding for many of the world's top pharmaceutical companies. Through this agreement, our ability to bridge into several major product categories is a certainty," said Brian Tuffin, Fuse Science President and Chief Operating Officer. "Our strong working relationship will accelerate our commercialization efforts."

Under the terms of the agreement, PDT Inc. will oversee a team of scientists facilitating the formulation and manufacturing of several Fuse Science products that leverage the Company's industry-leading Fusome Technology. The team's focus will be ongoing product innovation while working to advance Fuse Science's technology, intellectual property and patents. Rob Davidson, the team's managing director, reported today that PDT Inc. has already completed work on three new industry standards and proprietary formulations as Fuse Science prepares to enter the sports nutrition and performance categories. These are:

  • EnerJel – For active muscle fatigue, a real time anti-inflammatory and energy source applied directly to the problem area to help athletes finish the game
  • PowerDrops – Concentrated electrolyte delivery in a single drop before the game for stronger, sustained performance
  • EnergyDrops – An all-natural, faster-acting energy source with longer-lasting results in a single drop

"It is our firm belief that through the Fuse Science formulary technology, we can deliver user benefits faster and more effectively than typical sports drinks, pills and gels that are currently available on the market," added Dr. Edward Maliski, PDT Inc.'s Director of Research and Development.

Fuse Science products will be manufactured in full compliance with current good manufacturing practices (cGMP) set forth by the U.S. Food and Drug Administration, and as the company advances into larger categories, it intends to further maintain strict adherence to all FDA and regulatory compliance standards. In addition, because one of the natural markets for Fuse Science products is in the athletic and fitness space, extreme care has been taken to ensure that all of the company's products are in compliance with the banned substances policies of the world's major sports leagues.

Davidson's PDT Inc. team includes Dr. Maliski and Dr. Eric E. Allen. Dr. Maliski is an accomplished research scientist with 30 years' experience in the development of pharmaceutical and biotechnology products, and whose background includes work for the Sterling Winthrop Research Institute, Glaxo Research Institute, Merck & Co., and Amgen Inc. A recognized authority in the pharmaceutical industry for his work in drug discovery, Dr. Allen is an inventor on 16 drug-related, issued U.S. patents and brings nearly 25 years of pharmaceutical industry experience, including 10 years at Merck & Co.

"This is another key step in the journey to significant shareholder value," added Tuffin. "We have a tremendous science platform to build on, and this partnership will enhance our efforts. In the coming days and weeks we will begin to announce further strategic partnerships and endorsements from several of America's most notable athletes."

About Double Eagle Holdings

Double Eagle Holdings (OTCQB: DEGH) is an innovative consumer products holding company and the parent company of Fuse Science, Inc. Based in Aventura, Florida, Fuse Science is the developer of patent-pending conveyance technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, delivering their benefits faster and more effectively than ever before. Information about Fuse Science is available online at www.fusescience.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the company's SEC filings. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.


'/>"/>
SOURCE Double Eagle Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
2. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
3. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
4. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
5. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
6. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
7. Gaining Too Much Weight During Pregnancy Nearly Doubles Risk of Having a Heavy Baby
8. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
9. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
10. Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
11. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Pa. , Dec. 5, 2016  Pennsylvania Physician ... Drug and Alcohol Programs Gary Tennis today ... drug, at Minnich,s Pharmacy in York ... order signed by Dr. Levine as a prescription to ... "It,s important to remember that any Pennsylvanian ...
(Date:12/5/2016)... India , December 5, 2016 According ... by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free ... published by MarketsandMarkets, the market is projected to reach USD 779.8 ... a CAGR of 13.5% during the forecast period of 2016 to ... ...
(Date:12/5/2016)... Sanovas, Inc., a life science asset holding company ... wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed Intubation ... http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed annually ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... December 06, 2016 , ... "Add realistic flares and light ... and flare from clip to clip with high quality 4K lens flare footage," said ... contains 44 lens flares filmed on the RED Dragon. Utilizing the Dragon Sensor, TransFlare ...
(Date:12/5/2016)... ... December 05, 2016 , ... What: Shriners Hospitals for ... North Pole to our patients – using a video monitor and web-enabled camera. Santa ... will transform the Auditorium into a Christmas Wonderland, which is where the video connection ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward ... to announce the arrival of the newest Sciton laser in January 2017. The ... use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, ...
(Date:12/5/2016)... Ill. (PRWEB) , ... December 06, 2016 , ... For ... Lithuanian poetry , both thick and thin. The beauty of the Lithuanian ... by Trafford Publishing). , In this poetry book, Zubinas lyrically explores all aspects of ...
(Date:12/5/2016)... , ... December 05, 2016 ... ... security executive networking and relationship-marketing firm, announced today that nominations will be ... Information Security Executive® (ISE®) Central Awards. , Awards include the Information Security ...
Breaking Medicine News(10 mins):